Inhibrx Biosciences, Inc. (INBX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$121.17-0.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INBX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress ongoing clinical trials for INBRX-106 and ozekibart, including data readouts and regulatory interactions.
Stated as a priority in 3 of last 3 quarters. Management consistently emphasized advancing clinical trials for INBRX-106 and ozekibart, including planned data readouts in 2026 and regulatory milestones such as the FDA acceptance of the ozekibart BLA with a PDUFA date in April 2027. The trajectory shows active progress with ongoing studies and regulatory engagement, delivering on stated clinical development goals.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company has two programs in ongoing clinical trials with upcoming data readouts and FDA meetings planned.”
“Plans to announce PFS data from INBRX-106 Phase 2 trial and ongoing Phase 1/2 study of ozekibart in CRC.”
“Updated interim data announced for INBRX-106 and ozekibart; BLA submitted for ozekibart.”
Control operating expenses and cash burn while progressing clinical programs to extend financial runway.
Stated as a priority in 3 of last 3 quarters. The company reported net losses of $33.4M in 2026-Q1 and $36.7M in 2026-Q2, with cash balances declining from $161.7M to $133.3M over the same period. Despite ongoing losses and cash burn, management continues to focus on managing expenses to support clinical progress. The trajectory shows ongoing cash consumption consistent with clinical-stage biopharma operations, indicating limited progress in reducing burn but consistent management attention.
“Net loss was $36.7 million and cash and cash equivalents were $133.3 million as of June 30, 2026.”
“Net loss was $33.4 million with cash and cash equivalents of $161.7 million as of March 31, 2026.”
“Operating loss was $30.9 million with cash and cash equivalents of $124.2 million as of December 31, 2025.”
Secure and manage financing facilities to support clinical development and operational needs.
Stated as a priority in 2 of last 3 quarters. Management secured additional financing through amendments to the loan agreement with Oxford Finance, receiving $75 million in 2026-Q1 and $100 million in 2026-Q2, expanding the total credit facility to $500 million. This demonstrates active capital management to maintain resources supporting clinical and operational needs, delivering on financing objectives.
“Entered second amendment to Loan and Security Agreement with Oxford, receiving $100 million and up to $225 million more.”
“Received $75 million gross proceeds from first amendment to Loan and Security Agreement with Oxford.”
Over the trailing year it converted 0.92x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
10 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.